Vaccinations for Patients With Cancer and Cancer Survivors

Patients with cancer and cancer survivors are vulnerable to infection, rendering vaccination a necessary intervention. The vaccination process represents a unique challenge in these populations—it is often impossible or impractical to delay the start of cancer treatment for immunizations, and vaccines may fail to trigger an appropriate protective immune response in immunocompromised patients and cancer survivors, with residual immune deficits. Additionally, live attenuated vaccines are contraindicated due to an increased risk of prolonged shedding and disease presence. The current NCCN Guidelines for Survivorship, which reflect the most up-to-date, evidence-based data relating to survivorship, detail the appropriate immunization practices in these highly susceptible populations.

Disclosures: Dr. Rodriguez has disclosed having no relevant financial relationships.

Correspondence: Maria Alma Rodriguez, MD, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 11.6052, Houston, TX 77030. Email: marodriguez@mdanderson.org
  • 1.

    Sanft T, Tevaarwerk A, Ansbaugh S, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Survivorship. Version 1.2022. Accessed April 4, 2022. Available at NCCN.org

    • Search Google Scholar
    • Export Citation
  • 2.

    Heron M. Deaths: leading causes for 2019. Nat Vital Stat Rep 2021;70.

  • 3.

    Murphy SL, Kochanek KD, Xu JQ, et al. Mortality in the United States, 2020. NCHS Data Brief 2021;427.

  • 4.

    Peters ZJ, Ashman JJ, Schwartzman A, et al. National hospital care survey demonstration projects: examination of inpatient hospitalization and risk of mortality among patients diagnosed with pneumonia. Nat Health Stat Rep 2022;167.

    • Search Google Scholar
    • Export Citation
  • 5.

    Curtin SC, Spencer MR. Trends in death rates in urban and rural areas: United States, 1999–2019. NCHS Data Brief 2021;417.

  • 6.

    Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the advisory committee on immunization practices—United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:109117.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Centers for Disease Control and Prevention. COVID-19 vaccines for moderately or severely immunocompromised people. Accessed April 4, 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html

    • Search Google Scholar
    • Export Citation
  • 8.

    Recommendations of the National Comprehensive Cancer Network (NCCN) Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. Accessed April 1, 2022. Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v5-0.pdf?sfvrsn=b483da2b_80#:∼:text=The%20NCCN%20Committee%20recommends%20that,the%20preferred%20vaccine(s)

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 622 622 622
PDF Downloads 273 273 273
EPUB Downloads 0 0 0